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Summary.-Thirty patients with symptoms of the carcinoid syndrome and other
symptoms not controlled by pharmacological agents were analysed with respect to
the value ofvarious treatment measures used. Tumour devascularization was carried
out in 11 patients, either by surgical ligation of the main hepatic artery (6) or by
percutaneous arterial embolization (5). The latter was shown to be the safer techni-
que, both with respect to initial morbidity/mortality and other side effects. Control
of flushing and diarrhoea was achieved in 80% and the technique was also repeated
on one occasion with success when symptoms recurred. The use of cytotoxic drugs
alone,including5-fluorouracil,cyclophosphamide and Adriamycin produced sympto-
matic relief in only 4 of the 22 patients treated. They should only be considered if
devascularization by arterial embolization proves impossible or cannot be repeated
when symptoms recur.
ALTHOUGH THE PRESENCE of the car-
cinoid syndrome almost invariably implies
hepatic metastases, some of the tumours
continue to grow only slowly and patients
may live for many years. Various pharma-
cological agents can be helpful in the
control of the diarrhoea and flushing,
including methysergide, a 5-hydroxytrypt-
amine (5-HT) antagonist (Peart &
Robertson, 1961), parachlorophenylala-
nine (PCPA), an inhibitor of 5-HT
synthesis (Engelman et al., 1967) and
cyproheptadine, a 5-HT antagonist.
Chlorpromazine, by its o-adrenergic block-
ing effect and by allaying stressful situa-
tions which frequently provoke symptoms
(Farndon, 1977), and propranolol may
give partial relief of flushing (Zeegen
et al., 1969).
However, in some patients the condition
is resistant, and the alternative approach
is a direct attack to reduce the size of
functioning tumour mass on which the
severity of symptoms depends, by using
cytotoxic drugs. 5-Fluorouracil (Davis
et al., 1973; Moertel, 1975), cyclophos-
phamide, melphalan (Legha et al., 1977),
streptozotocin (Schein, et al., 1974) and
Adriamycin (Solomon et al., 1976; Legha
et al., 1977) have been shown to be of
some value, but appear to be much less
effective in patients with the carcinoid
syndrome than in those with asympto-
matic, possibly more malignant, metasta-
tic carcinoid (Legha et al., 1977).
In the present report we have reviewed
our experience with 30 patients referred
over the last 10 years with symptoms
of the carcinoid syndrome, or other
symptoms such as severe pain not con-
trollable by pharmacological agents, in
whom various chemotherapeutic schedules
and hepatic-devascularization techniques
have been used. Specific monitoring
with urinary 5-hydroxyindoleacetic acid
(5HIAA) concentrations has allowed ob-
jective assessment of the responses.
PATIENTS AND METHODS
Thirty patients were referred to the Liver
Unit between 1969 and 1979. Sixteen were
male and 14 female, with a median age atW. M. MELIA, H. B. NUNNERLEY, P. J. JOHNSON AND R. WILLIAMS
diagnosis of 56-5 years (range 24-76). The
site of the primary tumour was ascertained
in 22 patients as ileum (13), colon (3),
bronchus (2), pancreas (2), caecum (1)
and rectum (1). Primary resection had been
performed in 14 patients, mainly on account
of the development of intestinal obstruction.
The hepatic tumour deposits appeared to
be multiple on the basis of the vascular
pattern seen on selective hepatic angio-
graphy in 14/21 patients, whilst theremainder
appeared to have solitary lesions.
Symptoms leading to referral were un-
controlled diarrhoea (28 patients) and flush-
ing (25). In 2 patients, the major symptom
was severe right subcostal pain with weight
loss. Cardiac involvement was detected in
16 patients, 10 of whom had pulmonary
stenosis and 7 tricuspid incompetence. Methy-
sergide had been used to control diarrhoea
with partial success in 10/15 patients treated,
3 of whom also received codeine phosphate.
One of 3 patients treated with indomethacin
had shown temporary improvement of diar-
rhoea. Eight patients had been treated with
cyproheptadine, with no appreciable success,
whilst partial relief of flushing had been
achieved in 2/3 patients given propranolol.
A variety of other agents-flufenamic acid
(3), parachlorophenylalanine (1), phenoxy-
benzamine (1), chlorpromazine (1) and tri-
fluoperazine (1)-had been used, without
obvious benefit.
Devascularization and cytotoxic regimens.-
Devascularization procedures were performed
in 11 patients, by ligation ofthe main hepatic
artery at laparotomy in 5, by selective
ligation of the right hepatic artery supplying
the main tumour mass in 1, and by percu-
taneous arterial embolization (usually at
the time ofinitial arteriographic examination)
in the remainder. In 1 patient, embolization
was repeated on one occasion. Embolization
was performed by injecting chopped-up gel
foam mixed with contrast medium into
selectively catheterized branches of the
hepatic artery supplying tumour, under
general anaesthesia. Because of the danger
of release of vasoactive agents as a result of
the necrosis induced, patients were pro-
phylactically given blocking agents for
4 days beforehand: PCPA 500 mg q.d.s.,
cyproheptadine 4 mg q.d.s. and methy-
sergide 3 mg q.d.s. Prophylactic antibiotics
weregiven:benzyl-pencillin 1 megaunitq.d.s.,
gentamicin 80 mg t.d.s. and metronidazole
500 mg q.d.s. i.v.-for at least 7 days after
embolization.
Cytotoxicdrugs usedincluded5-fluorouracil
(FU, 15 patients), cyclophosphamide (CTX,
6), and Adriamycin (Adr, 3). FU was
given by intra-arterial infusion in 12
patients for periods of 1-14 days, total
doses being 0-3-18A4 g. In an attempt to
reduce the risk of release of vasoactive
agents, this technique was used as a pre-
liminary step before ligation in 5, while it
was used subsequent to ligation in 1 of these
and in 1 other patient. In 3 patients, FU
was given by portal-vein infusion, whilst
8 were treated with i.v. FU. CTX was
administered orally to 6 patients in doses
of 50-100 mg/day. Three were treated with
i.v. Adr in a dose of 60 mg/M2. One patient,
in whom i.v. FU appeared to have no
effect, was given a combination of oral CTX
(600 mg), i.v. MTX (40 mg), vincristine
(2 mg) and FU (2-5 g), while another was
given combined CTX and vinblastine for
4 years.
RESULTS
Devascularization procedures
Reduction in frequency and severity of
diarrhoea and flushing occurred in 3/6
patients treated by hepatic-artery liga-
tion, in 2 of whom improvement was
temporarily complete (11 and 65 months,
respectively) (Table). This was accom-
panied by a marked reduction in urinary
5-hydroxyindoleacetic acid (5HIAA) con-
centration (Fig. 1) which was recorded
in 1 other patient without symptom
relief (mean fall: 94 + 8%). Reduction
in liver size appeared to occur in only
1 patient, in whom a 50% reduction
in liver span in the right mid-clavicular
line was clinically detected. Postoperative
complications (fluctuations in blood pres-
sure (2), peritonitis (1), septicaemia (1),
hallucinations (1), marked exacerbation
of flushing lasting 3 days (1)) arose in
4/6 patients, 2 of whom died 3 and 6 days
later respectively.
After arterial embolization 4/5 patients
noted symptomatic improvement, and
this was accompanied by a fall in urinary
5HIAA excretion (mean: 79+ 15%; Fig.
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2). The procedure was followed by fluctua-
tions in blood pressure in 2 patients,
delayed awakening with a prolonged
confusional state in 2, and 1 woman with
severe pulmonary stenosis and the highest
urinary 5HIAA concentrations seen (1032
mg/24 h) died within a week of emboliza-
tion from right-sided cardiac failure.
Including both types of devasculariza-
tion techniques together, symptomatic
relief resulted in 7/11 patients treated.
The mean duration of symptomatic re-
mission was 13-5 months (range 7-65),
and remission lasted > 1 year in 4 and
> 2 years in 1 patient.
Cytotoxic drugs
Of the 15 patients given FU, complete
control of flushing and diarrhoea lasting
4.5 months was achieved in 1 patient, in
whom there was no evidence of reduction
in liver size. A 50% reduction in liver
span in the right midelavicular line was
detected clinically in 1 other patient,
who did not have a symptomatic response,
and there was some reduction in urinary
5HIAA output in 2 others (33% and
70% respectively). Complications followed
the use of intra-arterial FU in 10/12
patients thus treated, with septicaemia
in 5 patients (2 of whom died), catheter
obstruction in 2 and common iliac artery
thrombotic obstruction consequent on
catheter displacement in 1. No complica-
tions resulted from intraportal FU infu-
sion (3 patients) but 4/8 patients given
i.v. FU developed complications (septi-
caemia 3, dysgeusia 1) and 2 died from
sepsis.
One of 3 patients treated with Adr
experienced partial relief of diarrhoea
and pain lasting 6 months, and no patients
suffered side-effects. There was no evi-
dence of drug response in any of the 6
patients given CTX, none ofwhomsuffered
side-effects. The single patient treated
with combined CTX/MTX/vincristine/FU
died within 1 week from sepsis complicat-
ing myelosuppression, but the patient
given combined CTX and vinblastine
had prolonged symptom relief (9 months).
Survival analysis in relation to treatment
schedules
When survival of the total series of
patients from the onset of symptoms of
the carcinoid syndrome was determined
by the life-table method (Fig. 3), 1- and
2-year survival rates of 90% and 76%
respectively were obtained. Five-year
survival was 44% and 10-year survival
16%. Mean symptom duration before
diagnosis was 30 months. When survival
was measured from time of diagnosis
(Fig. 4) 1- and 2-year survival rates of
58% and 38% respectively were obtained,
whilst the 5-year survival was 23%.
The overall survival from diagnosis of
those patients treated by hepatic-arterial
ligation was similar to survival of the
total series: 50% 1-year and 17% 2-year
survival. After arterial embolization, the
corresponding figures were 80% and 80%
and, with the exception of the patient
dying within a week of the procedure,
the others are still alive at 19, 24, 24, and
and 26 months respectively. For the
series of 15 patients treated with FU,
1-year survival was 37% and 2-year, 15%.
DISCUSSION
Although our series of patients is a
highly selected one, because they had
refractory symptoms referred to a special-
ist unit, it is interesting that, when
measured from the first related symptom,
the survival figures obtained are very
similar to those reported by Davis et al.
(1973), who found that median life-span
from the first episode of flushing in 60
patients was 38 months, with a 6-year
survival rate of 25%. Despite this rela-
tively good prognosis, therapeutic inter-
vention is frequently indicated, both to
control troublesome symptoms and also
to induce tumour regression, as only 58%
of the patients in this series survived 1
year from the time of diagnosis.
Of the various pharmacological agents
used to control diarrhoea and flushing,
methysergide helped control diarrhoea
in only one-third of those we treated,
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FIG. 1.-Reduction in urinary 5HIAA concentratiofns following hepatic-artery ligation in a 53-
year-old woman with the carcinoid syndrome. This was accompanied by complete control of
diarrhoea for 11 months and a 50% reduction in liver span.
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FIG. 2. Reduction in urinary 5HIAA concentrations following selective hepatic artery embolization
in a 32-year-old woman with the carcinoid syndrome. This was accompanied by control of
diarrhoea and flushing for 9 months. When symptoms recurred, embolization was repeated.
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FIG. 3.-Life-table analysis of survival from symptom onset in the total series of
30 patients with the carcinoid syndrome.
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FIG. 4.-Life-table analysis of survival after diagnosis in the total series of 30 patients
with the carcinoid syndrome.W. M. MELIA, H. B. NUNNERLEY, P. J. JOHNSON AND R. WILLIAMS
and most of these were simultaneousy
treated with simple anti-diarrhoea agents,
while we found it ofno value in the control
offlushing. Neither chlorpromazine, phen-
oxybenzamine, trifluoperazine, PCPA or
cyproheptadine were of any value, but
2/3 patients treated with propranolol
did have partial relief of flushing.
For the patients whose symptoms
cannot be controlled by blocking agents,
attempts may be made surgically to
reduce the bulk of secreting tumour
cells. Although partial hepatectomy is
very effective in this regard, it is rarely
possible, due to the frequent multi-
centric nature of the tumour, though
enucleation of the largest metastases
may alleviate symptoms (Stephen &
Grahame Smith, 1972). Furthermore, the
fluctuations in blood pressure often noted
in these patients under anaesthesia may
complicate the procedure, which carries
a significant mortality. Hepatic-artery
ligation has been proposed as an effective
method both for reducing tumour bulk
and for relieving patients' symptoms
(Murray-Lyon et al., 1970; Farndon,
1977), but our results indicate that post-
operative complications are common
(67%) and sometimes fatal (33%). How-
ever, symptomatic improvement did sub-
sequently occur in half the patients
treated, accompanied by marked falls
in urinary 5HIAA, though reduction in
liver span was documented in only 1 of
the 6 patients.
The alternative technique of hepatic-
artery embolization was first used to
treat this condition in 1977 (Allison et al.,
1977). All the complications we encoun-
tered were related to the carcinoid state,
and the patient who died had the highest
urinary 5HIAA output ofthe 5 and severe
pulmonary stenosis, suggesting that cau-
tion must be exercised in those with
severe symptoms and cardiac involve-
ment. Prolonged symptomatic relief has
been achieved in 80% of the patients
treated (i.e. all the survivors).
The role of cytotoxic drugs in manag-
ing this condition has not been defined.
Reports indicate that FU has some
anti-carcinoid activity (Davis et al., 1973;
Moertel, 1975) and others have found
CTX and melphalan useful, with 25%
and 30% response respectively (Legha
et al., 1977). Despite initially encouraging
results, streptozotocin has been found to
have limited activity (Schein et al., 1974).
Although 2/10 patients with metatastic
carcinoid given combined FU and strepto-
zotocin achieved remission (Chernicoff
et al., 1979), neither had symptoms or
signs of the carcinoid syndrome and,
though urinary 5HIAA output fell in the
2 patients with the syndrome, there was
no other evidence of reduced tumour
bulk and no symptom relief. Moertel &
Harley (1978), in a series of 118 patients
with metastatic carcinoid, report a 32%
response for combined FU/streptozotocin
and 29% for CTX/streptozotocin. Only
1/15 patients we treated with either
i.v. or regional (intra-arterial or intra-
portal) FU had relief of symptoms and
there was evidence of tumour regression
in only 13% of patients.
Similarly, oral CTX did not produce
any remission, though the one patient
treated with combined CTX and vin-
blastine had prolonged symptomatic re-
lief. Higher response rates for combined
CTX and MTX have been claimed,
compared with their activity alone (Men-
gel & Shaffer, 1973).
Following a report that Adriamycin
might be effective (Solomon et al., 1976),
reports appeared of partial remission in
5/7 patients treated with Adr-containing
drug combinations (5) or Adr-DNA Com-
plex (2) (Legha et al., 1977). The only
other 2 partial remissions, out of a total
of 33 patients treated in this reported
series, were with combined CTX/MTX
and combined CTX/MTX/FU/vincristine/
bleomycin. Siklos (1978) has reported a
26-fold increase in urinary 5HIAA output
in a patient with the syndrome treated
with combined Adr/MTX/CTX. Although
the number we have treated with Adr is
small (3 patients), it is discouraging that
only limited symptom relief was achieved
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in 1 patient. Finally, there has recently
been a report describing the presence of
oestrogen receptors in carcinoid metasta-
ses, and remission has been induced
in a single patient given the anti-oestrogen
tamoxifen (Stathopoulos et al., 1981),
and further trials of this approach with
or without cytotoxic drugs are awaited
with interest.
This work was supported by a grant from the
Cancer Research Campaign.
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